Mekonos

We are a Silicon Valley chip technology startup aimed primarily toward cancer immunotherapy, gene engineering and drug development.

Launch date

May 2017

Employees

Market cap

Enterprise valuation

San Francisco California (HQ)

Date	Investors	Amount	Round
-	Matu dRx Capital Berkeley SkyDeck Section 32 QB3	N/A	-
Jul 2016	N/A	$50.0k	Convertible
Oct 2016	N/A	$250k	Grant
Jan 2017	University of Canterbury	N/A	Grant
Mar 2017	National Science Foundation University of Canterbury	$50.0k	Grant
Aug 2017	University of Canterbury	$200k	Grant
Oct 2017	Berkeley SkyDeck Fund Creative Destruction Lab	N/A	-
Jun 2018	Novartis Good AI Capital Elementum Ventures	$1.0m	Seed
Jan 2019	N/A	N/A	Seed
Dec 2020	Novartis CRCM Ventures Good AI Capital Elementum Ventures Hike Ventures	$4.6m	Early VC
Nov 2021*	Sands Capital Management PEAK6 Debiopharm Group Novartis Section 32 Elementum Ventures Reimagined Ventures TDK Ventures Fiscus Ventures	$25.0m	Series A
Total Funding		AUD48.5m

Tech stackLearn more about the technologies and tools that this company uses.

Recent News about Mekonos